DSGN Design Therapeutics Inc

Price (delayed)

$10.76

Market cap

$672.04M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.2

Enterprise value

$661.47M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 7

Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on ...

Highlights
The quick ratio has grown by 30% from the previous quarter but it has contracted by 22% YoY
Design Therapeutics's equity has decreased by 4.3% YoY but it has increased by 2.6% QoQ
DSGN's debt has surged by 67% year-on-year
DSGN's net income is down by 24% YoY

Key stats

What are the main financial stats of DSGN

DSGN stock price

How has the Design Therapeutics stock price performed over time
Intraday
3.07%
1 week
0.19%
1 month
-18.3%
1 year
162.44%
YTD
14.71%
QTD
1.13%

Financial performance

How have Design Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$78.76M
Net income
-$69.71M
Gross margin
N/A
Net margin
N/A
DSGN's net income is down by 24% YoY
DSGN's operating income is down by 15% year-on-year

Price vs fundamentals

How does DSGN's price correlate with its fundamentals

Growth

What is Design Therapeutics's growth rate over time

Valuation

What is Design Therapeutics stock price valuation
P/E
N/A
P/B
3.04
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 21% year-on-year
DSGN's P/B is 74% above its 5-year quarterly average of 1.7 and 40% above its last 4 quarters average of 2.1
Design Therapeutics's equity has decreased by 4.3% YoY but it has increased by 2.6% QoQ

Efficiency

How efficient is Design Therapeutics business performance
DSGN's ROE is down by 45% YoY
Design Therapeutics's ROA has decreased by 42% YoY
The company's return on invested capital fell by 39% YoY

Dividends

What is DSGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DSGN.

Financial health

How did Design Therapeutics financials performed over time
DSGN's current ratio is up by 30% since the previous quarter but it is down by 21% year-on-year
The quick ratio has grown by 30% from the previous quarter but it has contracted by 22% YoY
DSGN's debt is 99% smaller than its equity
DSGN's debt has surged by 67% year-on-year
Design Therapeutics's equity has decreased by 4.3% YoY but it has increased by 2.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.